These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

296 related items for PubMed ID: 17474542

  • 1. Monitoring effects of direct FXa-inhibitors with a new one-step prothrombinase-induced clotting time (PiCT) assay: comparative in vitro investigation with heparin, enoxaparin, fondaparinux and DX 9065a.
    Graff J, Picard-Willems B, Harder S.
    Int J Clin Pharmacol Ther; 2007 Apr; 45(4):237-43. PubMed ID: 17474542
    [Abstract] [Full Text] [Related]

  • 2. Monitoring direct FXa-inhibitors and fondaparinux by Prothrombinase-induced Clotting Time (PiCT): relation to FXa-activity and influence of assay modifications.
    Harder S, Parisius J, Picard-Willems B.
    Thromb Res; 2008 Apr; 123(2):396-403. PubMed ID: 18571698
    [Abstract] [Full Text] [Related]

  • 3. Global anticoagulant effects of a synthetic anti-factor Xa inhibitor (DX-9065a): implications for interventional use.
    Tobu M, Iqbal O, Ma Q, Schultz C, Jeske W, Hoppensteadt D, Lewis B, Fareed D, Fareed J.
    Clin Appl Thromb Hemost; 2003 Jan; 9(1):1-17. PubMed ID: 12643318
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Comparison of the effect of fondaparinux and enoxaparin on thrombin generation during in-vitro clotting of whole blood and platelet-rich plasma.
    Gerotziafas GT, Depasse F, Chakroun T, Van Dreden P, Samama MM, Elalamy I.
    Blood Coagul Fibrinolysis; 2004 Mar; 15(2):149-56. PubMed ID: 15091002
    [Abstract] [Full Text] [Related]

  • 6. Differential effects of DX-9065a, argatroban, and synthetic pentasaccharide on tissue thromboplastin inhibition test and dilute Russell's viper venom test.
    Gerbutavicius R, Iqbal O, Messmore HL, Wehrmacher WH, Hoppensteadt DA, Gerbutaviciene R, Griniute R, Fareed J.
    Clin Appl Thromb Hemost; 2003 Oct; 9(4):317-23. PubMed ID: 14653441
    [Abstract] [Full Text] [Related]

  • 7. DX-9065a inhibition of factor Xa and the prothrombinase complex: mechanism of inhibition and comparison with therapeutic heparins.
    Rezaie AR.
    Thromb Haemost; 2003 Jan; 89(1):112-21. PubMed ID: 12540961
    [Abstract] [Full Text] [Related]

  • 8. Antithrombotic effects of DX-9065a, a direct factor Xa inhibitor: a comparative study in humans versus low molecular weight heparin.
    Shimbo D, Osende J, Chen J, Robbins J, Shimoto Y, Kunitada S, Fuster V, Badimon JJ.
    Thromb Haemost; 2002 Nov; 88(5):733-8. PubMed ID: 12428086
    [Abstract] [Full Text] [Related]

  • 9. In vitro comparison of the effect of heparin, enoxaparin and fondaparinux on tests of coagulation.
    Linkins LA, Julian JA, Rischke J, Hirsh J, Weitz JI.
    Thromb Res; 2002 Sep 01; 107(5):241-4. PubMed ID: 12479885
    [Abstract] [Full Text] [Related]

  • 10. Biomarkers and coagulation tests for assessing the biosimilarity of a generic low-molecular-weight heparin: results of a study in healthy subjects with enoxaparin.
    Kuczka K, Harder S, Picard-Willems B, Warnke A, Donath F, Bianchini P, Parma B, Blume H.
    J Clin Pharmacol; 2008 Oct 01; 48(10):1189-96. PubMed ID: 18716314
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Monitoring high-dose heparinization during cardiopulmonary by-pass--a comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity assays.
    Raivio P, Kuitunen A, Petäjä J, Ilveskero S, Lassila R.
    Thromb Haemost; 2008 Feb 01; 99(2):427-34. PubMed ID: 18278195
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Impact of antithrombin deficiency on efficacy of edoxaban and antithrombin-dependent anticoagulants, fondaparinux, enoxaparin, and heparin.
    Fukuda T, Kamisato C, Honda Y, Matsushita T, Kojima T, Furugohri T, Morishima Y, Shibano T.
    Thromb Res; 2013 Jun 01; 131(6):540-6. PubMed ID: 23673387
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Laboratory-monitored fondaparinux and coagulation activity in association with total hip replacement.
    Virtanen L, Salmela B, Leinonen J, Lemponen M, Huhtala J, Joutsi-Korhonen L, Lassila R.
    Blood Coagul Fibrinolysis; 2014 Sep 01; 25(6):597-603. PubMed ID: 24732174
    [Abstract] [Full Text] [Related]

  • 19. Determination of antithrombin-dependent factor Xa inhibitors by prothrombin-induced clotting time.
    Harenberg J, Giese C, Hagedorn A, Traeger I, Fenyvesi T.
    Semin Thromb Hemost; 2007 Jul 01; 33(5):503-7. PubMed ID: 17629847
    [Abstract] [Full Text] [Related]

  • 20. Determination of enoxaparin with rotational thrombelastometry using the prothrombinase-induced clotting time reagent.
    Schaden E, Schober A, Hacker S, Spiss C, Chiari A, Kozek-Langenecker S.
    Blood Coagul Fibrinolysis; 2010 Apr 01; 21(3):256-61. PubMed ID: 20087172
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.